Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 6646 AL 6660

Detection of Aβ plaques by a novel specific MRI probe precursor CR-BSA-(Gd-DTPA)n in APP/PS1 transgenic mice

Li S, He H, Cui W, Gu B, Li J, Qi Z, Zhou G, Liang CM, Feng XY.

Anat Rec (Hoboken). 2010 Dec;293(12):2136-43. doi: 10.1002/ar.21209.

Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer's disease trial

Wessels AM, Pollock BG, Anyama NG, Schneider LS, Lieberman JA, Marder SR, Bies RR.

J Clin Psychopharmacol. 2010 Dec;30(6):683-7. doi: 10.1097/jcp.0b013e3181fa05bb.

Synthesis and in vitro evaluation of N-(Bromobut-3-en-2-yl)-7-methoxy-1,2,3,4-tetrahydroacridin-9-amine as a cholinesterase inhibitor with regard to Alzheimer's disease treatment

Korabecny J, Musilek K, Holas O, Nepovimova E, Jun D, Zemek F, Opletalova V, Patocka J, Dohnal V, Nachon F, Hroudova J, Fisar Z, Kuca K.

Molecules. 2010 Dec 2;15(12):8804-12. doi: 10.3390/molecules15128804.

Roles of β-adrenergic receptors in Alzheimer's disease: implications for novel therapeutics

Yu JT, Wang ND, Ma T, Jiang H, Guan J, Tan L.

Brain Res Bull. 2011 Feb 1;84(2):111-7. doi: 10.1016/j.brainresbull.2010.11.004. Epub 2010 Dec 1.

Neuroprotective strategies involving ROS in Alzheimer disease

Dumont M, Beal MF.

Free Radic Biol Med. 2011 Sep 1;51(5):1014-26. doi: 10.1016/j.freeradbiomed.2010.11.026. Epub 2010 Dec 1.

Secretases as therapeutic targets for Alzheimer's disease

Woo HN, Baik SH, Park JS, Gwon AR, Yang S, Yun YK, Jo DG.

Biochem Biophys Res Commun. 2011 Jan 7;404(1):10-5. doi: 10.1016/j.bbrc.2010.11.132. Epub 2010 Dec 3.

Reviews: Effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's disease

Grossberg GT, Schmitt FA, Meng X, Tekin S, Olin J.

Am J Alzheimers Dis Other Demen. 2010 Dec;25(8):627-33. doi: 10.1177/1533317510385808.

Neurotherapeutic applications of nanoparticles in Alzheimer's disease

Sahni JK, Doggui S, Ali J, Baboota S, Dao L, Ramassamy C.

J Control Release. 2011 Jun 10;152(2):208-31. doi: 10.1016/j.jconrel.2010.11.033. Epub 2010 Dec 4.

Calcineurin inhibition with FK506 ameliorates dendritic spine density deficits in plaque-bearing Alzheimer model mice

Rozkalne A, Hyman BT, Spires-Jones TL.

Neurobiol Dis. 2011 Mar;41(3):650-4. doi: 10.1016/j.nbd.2010.11.014. Epub 2010 Dec 4.

Insulin-resistant brain state (IRBS) changes membrane composition of fatty acids in temporal and entorhinal brain cortices of rats: relevance to sporadic Alzheimer's disease?

Plaschke K, Müller D, Hoyer S.

J Neural Transm (Vienna). 2010 Dec;117(12):1419-22. doi: 10.1007/s00702-010-0523-3. Epub 2010 Dec 7.

γ-Secretase modulators as potential disease modifying anti-Alzheimer's drugs

Oehlrich D, Berthelot DJ, Gijsen HJ.

J Med Chem. 2011 Feb 10;54(3):669-98. doi: 10.1021/jm101168r. Epub 2010 Dec 9.

Genistein ameliorates learning and memory deficits in amyloid β(1-40) rat model of Alzheimer's disease

Bagheri M, Joghataei MT, Mohseni S, Roghani M.

Neurobiol Learn Mem. 2011 Mar;95(3):270-6. doi: 10.1016/j.nlm.2010.12.001. Epub 2010 Dec 7.

Targeting amyloid precursor protein secretases: Alzheimer's disease and beyond

Ganjei JK.

Drug News Perspect. 2010 Nov;23(9):573-84. doi: 10.1358/dnp.2010.23.9.1507297.

Short-term effect of combined drug therapy and cognitive stimulation therapy on the cognitive function of Alzheimer's disease

Matsuda O, Shido E, Hashikai A, Shibuya H, Kouno M, Hara C, Saito M.

Psychogeriatrics. 2010 Dec;10(4):167-72. doi: 10.1111/j.1479-8301.2010.00335.x.

Citicoline in vascular cognitive impairment and vascular dementia after stroke

Alvarez-Sabín J, Román GC.

Stroke. 2011 Jan;42(1 Suppl):S40-3. doi: 10.1161/STROKEAHA.110.606509. Epub 2010 Dec 16.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias